Author Archive

13 Recent IPOs added to BioPharmCatalyst: JUNO TCON ONCE NEOT ASND BLCM CHRS XENE ZSAN XENE HSGX FGEN NDRM

Jan 31, 2015 No Comments by

13 recent biotech IPOs up until January 30, 2015 have been added to the Company Pipeline Database. Companies with upcoming clinical data releases have also been added to the FDA Calendar: Many thanks to @AndyBiotech on twitter for keeping up with the IPOs. Ticker Price Drug Indication Stage Link Text Updated ASND 19.83 TransCon Growth […]

Articles Read more

ZGNX FDA Approval + updates for APPY CORT IMGN PCYC RDUS SGYP VCEL VRTX

Jan 31, 2015 No Comments by

Expect updates to be streaming in thick and fast over the next two weeks when most small-mid cap companies report 4Q 2014 results. Latest updates to the Company Pipeline Database for January 28-30, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated APPY 0.50 Appy1 Acute appendicitis […]

Daily News Read more

AMGN additions to the Pipeline Database and FDA Calendar

Jan 28, 2015 No Comments by

Latest updates to the Company Pipeline Database for January 27, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AMGN 158.89 Blinatumomab Acute Lymphoblastic Leukemia PDUFA PDUFA May 19, 2015. Priority review 1/28/2015 AMGN 158.89 ABP 501 (adalimumab) Moderate-to-severe rheumatoid arthritis Phase 3 Phase 3 data due […]

Daily News Read more

RMTI receives FDA Approval + updates for BCRX GEVA HTBX

Jan 26, 2015 No Comments

Latest updates to the Company Pipeline Database for January 26, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated BCRX 11.33 BCX4161 – OPuS-2 Hereditary angioedema Phase 2b Phase 2b data due by end of 2015 1/27/2015 GEVA 120.92 SBC-103 Mucopolysaccharidosis IIIB Phase 1/2 Phase 1/2 trial […]

Read more

Large cap PDUFA dates have been now added to BioPharmCatalyst. 20 in total today.

Jan 26, 2015 No Comments

20 PDUFA dates from mainly large cap companies have been added to the Company Pipeline Database and FDA Calendar. Previously, BioPharmCatalyst has focused on providing information more small and mid-cap companies but due to readership demand, large cap companies that have upcoming PDUFA dates will now appear in the database. A decision whether or not to also […]

Read more

NPSP FDA Approval. KYTH Advisory Committee Meeting + PGNX resumes Phase 2 trial

Jan 24, 2015 No Comments

Latest updates to the Company Pipeline Database for January 23, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated KYTH 35.28 ATX-101 Reduction of Localized Subcutaneous Fat in the Submental Area PDUFA PDUFA May 13 2015. Advisory Committee Meeting March 9 2015 1/25/2015 NPSP 45.64 Natpara Hypoparathyroidism […]

Read more

CYTR and MDVN release clinical data. ALXA initiates Phase 2 trial

Jan 22, 2015 No Comments

Latest updates to the Company Pipeline Database for January 22, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALXA 2.07 AZ-002 Acute repetitive seizures Phase 2 Phase 2 initiated late Jan 2014 1/23/2015 CYTR 3.01 Aldoxorubicin Cancer – soft tissue sarcomas first line Phase 2b Overall […]

Read more

Distinct lack of clinical news this week – updates for OCUL and CYTR

Jan 22, 2015 No Comments

There has been a noticeable lack of major clinical news over the last couple days following the JPM Conference last week and looking forward to the 4Q earnings season in a couple weeks. Latest updates to the Company Pipeline Database from January 20 and 21, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker […]

Read more

Latest updates for CUR TGTX TNXP

Jan 16, 2015 No Comments

Latest updates to the Company Pipeline Database from January 15, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated CUR 2.89 NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase 2 data are due LATE 1Q or EARLY 2Q 2015 according to Jan 2015 presentation. 1/16/2015 TGTX […]

Read more

ETRM receives FDA Approval. CUR Phase 2 ALS data due 2Q. OPK NDA filing update + RGDO BCRX news

Jan 15, 2015 No Comments

Latest updates to the Company Pipeline Database from January 14, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated BCRX 11.41 BCX4161 – OPuS-2 Hereditary angioedema Phase 2b Phase 2b data due by end of 2015 1/15/2015 CUR 3.09 NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase […]

Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Read more